Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Celcuity (CELC)
NASDAQ:CELC
Holding CELC?
Track your performance easily
Earnings Data
Report Date
Mar 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.71Last Year’s EPS
-$0.65Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: -11.69%
|Next Earnings Date:Mar 20, 2025
Earnings Call Sentiment|Positive
The earnings call demonstrated Celcuity's strong progress in its clinical trials and financial positioning, with significant milestones achieved for gedatolisib's development. Despite a higher net loss and operating cash use, the company maintains a robust cash position and anticipates substantial future revenue opportunities. The market feedback and safety profile of gedatolisib are promising, although trial event rates remain a challenge.Company Guidance
During the Celcuity Q3 2024 earnings call, the company provided guidance on several key metrics related to the clinical development of their drug, gedatolisib. They announced that the PIK3CA wild-type cohort in their Phase III VIKTORIA-1 trial is 100% enrolled, with the PIK3CA mutant cohort enrollment on track as planned. The primary endpoints for VIKTORIA-1 are progression-free survival (PFS) assessed by blinded independent central review, with top line data for the wild-type cohort expected in late Q1 or Q2 2025 and for the mutant cohort in the second half of 2025. A new drug application (NDA) filing is anticipated if results are positive. Additionally, the VIKTORIA-2 trial is set to enroll its first patient in Q2 2025, and preliminary data from a Phase Ib/II trial in prostate cancer is expected in Q2 2025. Financially, Celcuity reported a Q3 net loss of $29.8 million or $0.70 per share, with a non-GAAP adjusted net loss of $27.6 million or $0.65 per share, and ended the quarter with $264.1 million in cash and equivalents.Successful Enrollment in Phase III Trial
Celcuity announced that the PIK3CA wild-type cohort in their VIKTORIA-1 Phase III clinical trial is 100% enrolled, marking an important milestone for the company.
Strong Financial Position
Celcuity ended the quarter with approximately $264.1 million in cash, cash equivalents, and short-term investments, an increase of $83.5 million from the previous year.
Robust Research and Development Progress
Research and development expenses increased significantly, indicating active progress in clinical trials and enhanced operations.
Encouraging Safety Profile
Gedatolisib's treatment-related discontinuation rate in the Phase Ib arm was low at 4%, showing a promising safety profile compared to other treatments.
Positive Market Feedback
Feedback from oncologists and market access stakeholders was encouraging, particularly regarding gedatolisib’s IV administration route.
Potential Revenue Growth
Estimated peak revenue potential for gedatolisib in the second line and delayed indication could exceed $2 billion if approved.
---
CELC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CELC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $14.11 | $12.66 | -10.28% |
| Aug 14, 2024 | $16.33 | $15.77 | -3.43% |
| May 15, 2024 | $17.23 | $17.66 | +2.50% |
| Mar 27, 2024 | $18.16 | $21.60 | +18.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Celcuity (CELC) report earnings?
Celcuity (CELC) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
What is Celcuity (CELC) earnings time?
Celcuity (CELC) earnings time is at Mar 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CELC EPS forecast?
CELC EPS forecast for the fiscal quarter 2024 (Q4) is -$0.71.
---